Epidemiology of myomas

Mark Payson, Phyllis Leppert, James Segars

Research output: Contribution to journalArticle

Abstract

Fibroids are a prevalent disorder occurring in at least half of American reproductive-age women. In general, the incidence and size increases with age. Most women never attribute or report any symptoms from their fibroids, and because of this the actual contribution of disease to symptoms of pelvic pain, menstrual symptoms, and infertility is poorly understood. The presence of fibroids can lead to multiple and disabling difficulties. Fibroids may cause pain and menstrual bleeding to the point of anemia. Fibroids clearly reduce fertility, increase preterm labor and delivery, and markedly increase the risk for cesarean delivery. Because the incidence varies according to population of interest, fibroids may explain some health disparities in different populations. For example, African Americans have a relatively poor outcome with assisted reproductive techniques compared with whites [32]. Controlling for fibroid disease may explain this disparity, at least in part [33]. Fibroids represent a tremendous public health burden on women and economic cost on society. Strategies to prevent, limit growth, and treat nonsurgically are needed. Fundamental and significant questions remain about fibroid disease, such as whether different clinical disease phenotypes (multiple versus single leiomyomas) contribute equally to symptoms and possess an equal likelihood of disease progression. For epidemiologic assessment of disease, a scoring system is urgently needed. Well-designed, controlled, prospective studies are still needed to define the natural history and correlate the presence of disease with symptomatology in women [34].

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalObstetrics and Gynecology Clinics of North America
Volume33
Issue number1
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Myoma
Leiomyoma
Epidemiology
Dysmenorrhea
Assisted Reproductive Techniques
Pelvic Pain
Premature Obstetric Labor
Incidence
Natural History
African Americans
Infertility
Population
Fertility
Disease Progression
Anemia
Public Health
Economics
Prospective Studies
Hemorrhage
Phenotype

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Epidemiology of myomas. / Payson, Mark; Leppert, Phyllis; Segars, James.

In: Obstetrics and Gynecology Clinics of North America, Vol. 33, No. 1, 03.2006, p. 1-11.

Research output: Contribution to journalArticle

Payson, Mark ; Leppert, Phyllis ; Segars, James. / Epidemiology of myomas. In: Obstetrics and Gynecology Clinics of North America. 2006 ; Vol. 33, No. 1. pp. 1-11.
@article{fe566d28481b439bac754c834f7a6549,
title = "Epidemiology of myomas",
abstract = "Fibroids are a prevalent disorder occurring in at least half of American reproductive-age women. In general, the incidence and size increases with age. Most women never attribute or report any symptoms from their fibroids, and because of this the actual contribution of disease to symptoms of pelvic pain, menstrual symptoms, and infertility is poorly understood. The presence of fibroids can lead to multiple and disabling difficulties. Fibroids may cause pain and menstrual bleeding to the point of anemia. Fibroids clearly reduce fertility, increase preterm labor and delivery, and markedly increase the risk for cesarean delivery. Because the incidence varies according to population of interest, fibroids may explain some health disparities in different populations. For example, African Americans have a relatively poor outcome with assisted reproductive techniques compared with whites [32]. Controlling for fibroid disease may explain this disparity, at least in part [33]. Fibroids represent a tremendous public health burden on women and economic cost on society. Strategies to prevent, limit growth, and treat nonsurgically are needed. Fundamental and significant questions remain about fibroid disease, such as whether different clinical disease phenotypes (multiple versus single leiomyomas) contribute equally to symptoms and possess an equal likelihood of disease progression. For epidemiologic assessment of disease, a scoring system is urgently needed. Well-designed, controlled, prospective studies are still needed to define the natural history and correlate the presence of disease with symptomatology in women [34].",
author = "Mark Payson and Phyllis Leppert and James Segars",
year = "2006",
month = "3",
doi = "10.1016/j.ogc.2005.12.004",
language = "English (US)",
volume = "33",
pages = "1--11",
journal = "Obstetrics and Gynecology Clinics of North America",
issn = "0889-8545",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Epidemiology of myomas

AU - Payson, Mark

AU - Leppert, Phyllis

AU - Segars, James

PY - 2006/3

Y1 - 2006/3

N2 - Fibroids are a prevalent disorder occurring in at least half of American reproductive-age women. In general, the incidence and size increases with age. Most women never attribute or report any symptoms from their fibroids, and because of this the actual contribution of disease to symptoms of pelvic pain, menstrual symptoms, and infertility is poorly understood. The presence of fibroids can lead to multiple and disabling difficulties. Fibroids may cause pain and menstrual bleeding to the point of anemia. Fibroids clearly reduce fertility, increase preterm labor and delivery, and markedly increase the risk for cesarean delivery. Because the incidence varies according to population of interest, fibroids may explain some health disparities in different populations. For example, African Americans have a relatively poor outcome with assisted reproductive techniques compared with whites [32]. Controlling for fibroid disease may explain this disparity, at least in part [33]. Fibroids represent a tremendous public health burden on women and economic cost on society. Strategies to prevent, limit growth, and treat nonsurgically are needed. Fundamental and significant questions remain about fibroid disease, such as whether different clinical disease phenotypes (multiple versus single leiomyomas) contribute equally to symptoms and possess an equal likelihood of disease progression. For epidemiologic assessment of disease, a scoring system is urgently needed. Well-designed, controlled, prospective studies are still needed to define the natural history and correlate the presence of disease with symptomatology in women [34].

AB - Fibroids are a prevalent disorder occurring in at least half of American reproductive-age women. In general, the incidence and size increases with age. Most women never attribute or report any symptoms from their fibroids, and because of this the actual contribution of disease to symptoms of pelvic pain, menstrual symptoms, and infertility is poorly understood. The presence of fibroids can lead to multiple and disabling difficulties. Fibroids may cause pain and menstrual bleeding to the point of anemia. Fibroids clearly reduce fertility, increase preterm labor and delivery, and markedly increase the risk for cesarean delivery. Because the incidence varies according to population of interest, fibroids may explain some health disparities in different populations. For example, African Americans have a relatively poor outcome with assisted reproductive techniques compared with whites [32]. Controlling for fibroid disease may explain this disparity, at least in part [33]. Fibroids represent a tremendous public health burden on women and economic cost on society. Strategies to prevent, limit growth, and treat nonsurgically are needed. Fundamental and significant questions remain about fibroid disease, such as whether different clinical disease phenotypes (multiple versus single leiomyomas) contribute equally to symptoms and possess an equal likelihood of disease progression. For epidemiologic assessment of disease, a scoring system is urgently needed. Well-designed, controlled, prospective studies are still needed to define the natural history and correlate the presence of disease with symptomatology in women [34].

UR - http://www.scopus.com/inward/record.url?scp=33644541770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644541770&partnerID=8YFLogxK

U2 - 10.1016/j.ogc.2005.12.004

DO - 10.1016/j.ogc.2005.12.004

M3 - Article

C2 - 16504803

AN - SCOPUS:33644541770

VL - 33

SP - 1

EP - 11

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

SN - 0889-8545

IS - 1

ER -